摘要
目的:探讨Ahmed青光眼阀(AGV)植入术联合雷珠单抗治疗新生血管性青光眼(NVG)患者的效果。方法:选择2016年9月—2022年9月河池市第三人民医院收治的66例NVG患者作为研究对象,按照计算机分组法分为两组,各33例。对照组给予AGV植入术治疗,观察组在对照组基础上加用雷珠单抗治疗。比较两组临床疗效、眼压及视力的变化情况、眼动脉血流动力学及并发症发生率。结果:观察组总有效率为93.94%,高于对照组的75.76%,差异有统计学意义(P<0.05)。治疗1周、1个月、3个月后,观察组眼压水平低于对照组,术眼最佳矫正视力(BCVA)高于对照组,差异有统计学意义(P<0.05)。治疗3个月后,观察组舒张末期流速(EDV)、收缩期峰值流速(PSV)高于对照组,血流阻力指数(RI)低于对照组,差异有统计学意义(P<0.05)。两组并发症总发生率比较,差异无统计学意义(P>0.05)。结论:AGV植入术联合雷珠单抗具有良好的临床疗效,可有效改善NVG患者眼动脉血流动力学指标,促进眼部血液循环,以降低眼压,提高视力,且不增加并发症发生率。
Objective:To investigate the effect of Ahmed glaucoma valve(AGV)implantation combined with Ranibizumab in the treatment of patients with neovascular glaucoma(NVG).Method:A total of 66 patients with NVG admitted to the Hechi Third People's Hospital from September 2016 to September 2022 were selected as the study objects and divided into two groups according to the computer grouping method,with 33 patients in each group.The control group was treated with AGV implantation,and the observation group was treated with Ranibizumab on the basis of control group.The clinical efficacy,the changes of intraocular pressure and visual acuity,the hemodynamics of ocular artery and the incidence of complications were compared between the two groups.Result:The total effective rate of the observation group was 93.94%,which was higher than 75.76%of the control group,and the difference was statistically significant(P<0.05).After 1 week,1 month and 3 months of treatment,the intraocular pressure level of the observation group was lower than that of the control group,and the best corrected visual acuity(BCVA)of the operative eye was higher than that of the control group,the differences were statistically significant(P<0.05).At 3 months of treatment,end-diastolic flow velocity(EDV)and peak systolic flow velocity(PSV)in observation group were higher than those in control group,and blood flow resistance index(RI)was lower than that in control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of complications between the two groups(P>0.05).Conclusion:AGV implantation combined with Ranibizumab has good clinical efficacy,which can effectively improve the hemodynamic indexes of the eye arteries in patients with NVG,promote the blood circulation of the eye,reduce intraocular pressure,improve visual acuity,and do not increase the incidence of complications.
作者
卢晚霞
谭庆雄
LUWanxia;TAN Qingxiong(Hechi Third People's Hospital,Hechi 547000,China;不详)
出处
《中外医学研究》
2024年第17期121-125,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
